We are live on ! Find out more
RPRX

Repros Therapeutics Inc.
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

64 hedge funds and large institutions have $106M invested in Repros Therapeutics Inc. in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more call options, than puts

Call options by funds: $3.18M | Put options by funds: $2.96M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 7264 (-8)

21% less capital invested

Capital invested by funds: $135M → $106M (-$28.6M)

24% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 21

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

Holders
64
Holders Change
-8
Holders Change %
-11.11%
% of All Funds
1.72%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
16
Reduced
21
Closed
25
Calls
$3.18M
Puts
$2.96M
Net Calls
+$221K
Net Calls Change
-$5.18M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$26M +$3.87M +496,279 +16%
BBA
2
Baker Bros. Advisors
New York
$14M -$343K -44,056 -2%
SCM
3
Sarissa Capital Management
Connecticut
$8.1M
Millennium Management
4
Millennium Management
New York
$5.51M +$775K +99,519 +15%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.03M -$28.2K -3,620 -0.5%
BIT
6
BlackRock Institutional Trust
California
$4.57M -$1.65M -211,926 -25%
GAI
7
General American Investors
New York
$4.3M +$726K +93,178 +18%
Bank of America
8
Bank of America
North Carolina
$3.73M +$1.22M +156,186 +43%
Morgan Stanley
9
Morgan Stanley
New York
$2.6M +$1.15M +147,476 +68%
DCM
10
Destrier Capital Management
New York
$2.35M
GCM
11
Gruss Capital Management
New York
$2.17M
Northern Trust
12
Northern Trust
Illinois
$1.94M -$183K -23,437 -8%
HCMT
13
Highland Capital Management (Texas)
Texas
$1.77M -$615K -78,900 -24%
CC
14
CQS Cayman
Cayman Islands
$1.72M -$3.58M -460,000 -66%
RI
15
RTW Investments
New York
$1.64M
Renaissance Technologies
16
Renaissance Technologies
New York
$1.45M +$1.57M +202,143 New
CWG
17
C WorldWide Group
Denmark
$1.43M
RA
18
Royce & Associates
New York
$1.37M
EDRH
19
Edmond de Rothschild Holding
Switzerland
$1.3M +$1.42M +182,500 New
EDRS
20
Edmond de Rothschild (Suisse)
Switzerland
$1.3M +$1.42M +182,500 New
Fuller & Thaler Asset Management
21
Fuller & Thaler Asset Management
California
$1.21M +$28K +3,600 +2%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$970K +$149K +19,089 +16%
Deutsche Bank
23
Deutsche Bank
Germany
$956K +$444K +56,993 +74%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$917K -$47.7K -6,119 -5%
Goldman Sachs
25
Goldman Sachs
New York
$878K +$522K +66,965 +120%

RPRX Hedge Fund Activity: Q2 2015 in Review

64 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2015, worth a combined $106M — down 21% from $135M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of RPRX and 17 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 16 added.

The largest buyer was Fidelity Investments, adding an estimated $3.87M. The largest seller was BlackRock Fund Advisors, cutting an estimated $4.91M.

  • 64 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2015, down from 72 in Q1 2015.
  • Funds reported $106M of Repros Therapeutics Inc. stock for Q2 2015, down 21% quarter-over-quarter.
  • 17 funds opened new Repros Therapeutics Inc. positions in Q2 2015 and 25 closed out, a net change of -8 holders.
  • The largest Repros Therapeutics Inc. buyer in Q2 2015 was Fidelity Investments, an estimated $3.87M added.
  • The largest Repros Therapeutics Inc. seller in Q2 2015 was BlackRock Fund Advisors, an estimated $4.91M sold.

Based on aggregated 13F filings for Q2 2015.